Medical needles are used in mini-invasive percutaneous procedures and are deep-tissue inserted. ARC technology adds a mechanical option to medical needles allowing the correction of its trajectory and thus better reach the targeted tissue. Its main applications are biopsy and cancerous lesion treatment.

Nouvelles résines pour améliorer la protection balistique. Résines photopolymérisables rapidement sur les tissus d'aramide permettant la protection contre les balles et les fragments des véhicules et des personnes. Sans composés organiques volatils, le matériau préserve la santé des utilisateurs. Particulièrement adaptée aux véhicules blindés pour un coût d'équipements et d'utilisation avantageux.

New-infrared coating and implantable materials used as medical biosensors. Targeted applications for this new functionalized biomaterial: diagnostic detection for inflammatory and infectious processes, monitoring of patients suffering from chronic inflammatory diseases, monitoring of patients during or after surgical interventions

Potent Mn contrast agent ligand used for MRI. We develop Bispidine-based Mn2+ contrast agents with higher stability and relaxivity than standards, providing a safer alternative to Gadolinium contrast agents.

Small molecule (NCE) agonist of sigma1 receptor for the treatment of several neurodegenerative diseases. 2 chemical series, protected by 2 patents, highly selective and affine. Preliminary in-vivo data available on Alzheimer's, ALS (amyotrophic lateral sclerosis) and CIAS (cognitive impairement associated with schizophrenia) models.

Development of new photopolymerisable formulations (under UV or near-infrared LED light) for epoxy-amines resins. These formulations allow a polymerisation within minutes instead of hours, at room temperature without the necessity of thermal cure. Their application is in various fields and markets, such as composites, adhesives etc.

New gene therapy to treat Fragile X syndrome by targeting DGKk, new innovative therapeutic target validated in human tissues by the research team. We generated a first in-vivo proof of concept of DGKk gene therapy and patented the approach.

New antibody fragments for the treatment of thrombosis (stroke, thrombotic purpura, coronary syndrome...). Our approach is directed against a platelet receptor that is not currently targeted by commercially available products, and prevents thrombus formation with a reduced bleeding risk.

Light-Up Nucleic Acid technology based on a light-up RNA aptamer able to specifically recognize a fluorogen and light up a fluorescence signal.
Module with very good properties in term of brightness, photostability and signal to noise ratio. Could overcome current limitations of RNA imaging and could be applied in diagnostic to detect RNA targets with high specificity and sensibility.

Development of new photopolymerisable formulations for both epoxy and acrylic resins under near-infrared light. These formulations allow a polymerisation within seconds, the near-infrared light allows better penetration than UV and is safer for operators. The technology is an adapted solution for thick or filled samples where UV light fails. This technology targets various markets, such as electronics, automotive or coatings.